. . . . . . . "[Patients with previously treated or treatment-naive, unresectable stage IIIC or stage IV, BRAF (V600) mutation-positive melanoma received vemurafenib 960�mg twice daily until disease progression, unacceptable toxicity, withdrawal of consent or death.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2017-02-19"^^ . . "Gene-disease associations inferred from text-mining the literature."@en . "DisGeNET evidence - LITERATURE"@en . "2017-10-17T13:11:04+02:00"^^ . . . . . . . . . . . "v5.0.0.0" . "v5.0.0" .